List of Bludigo drug patents

Bludigo is owned by Provepharm Sas.

Bludigo contains Indigotindisulfonate Sodium.

Bludigo has a total of 2 drug patents out of which 0 drug patents have expired.

Bludigo was authorised for market use on 08 July, 2022.

Bludigo is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Bludigo from 2026-07-08.

The generics of Bludigo are possible to be released after 23 December, 2037.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(14 years from now)

Dec, 2037

(14 years from now)

Do you want to check out BLUDIGO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 8, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 2026-07-08

Market Authorisation Date: 08 July, 2022

Treatment: NA


More Information on Dosage

BLUDIGO family patents


United States




European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in